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Saúde Pública, Universidade do Porto, Porto, Porto, Portugal, 5 CIAFEL—Centro de Investigação em
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Abstract
Background
Vitamin D deficiency is common in older adults and has been linked with frailty and obesity,
but it remains to be studied whether frail obese older adults are at higher risk of vitamin D
deficiency. Therefore, the aim of this study is to explore the association between frailty, obe-
sity indices and serum 25(OH)D concentrations.
Methods
1447 individuals with 65 years or older, participating in a cross-sectional study (Nutrition UP
65) were included. Frailty, according to Fried et al., body mass index (BMI), waist circumfer-
ence (WC), body roundness index (BRI) and body shape index (ABSI) were evaluated. A
stepwise multinomial logistic regression was carried out to quantify the association between
25(OH)D quartiles and independent variables.
Results
Median 25(OH)D levels were lower in individuals presenting both frailty and obesity
(p<0.001). In the multivariate analysis, pre-frailty (OR: 2.65; 95% CI: 1.63–4.33) and frailty
(OR: 3.77; 95% CI: 2.08–6.83) were associated with increased odds of lower 25(OH)D
serum levels (first quartile). Regarding obesity indices, the highest categories of BMI (OR:
1.74; 95% CI: 1.06–2.86), WC (OR: 3.46; 95% CI: 1.95–6.15), BRI (OR: 4.35; 95% CI:
2.60–7.29) and ABSI (OR: 3.17 95% CI: 1.86–5.38) were directly associated with lower 25
(OH)D serum levels (first quartile).
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Conclusions
A positive association between frailty or obesity and lower vitamin D levels was found. More-
over, besides BMI and WC, other indicators of body adiposity, such as BRI and ABSI, were
associated with lower 25(OH)D serum concentrations.
Introduction
Vitamin D is fat-soluble vitamin mainly obtained from sun exposure of the skin and in lesser
amounts from diet and supplements [1–3]. It is stored mainly in adipose tissue and muscle
and, to a lesser extent, in other tissues [4]. Vitamin D deficiency is a public health problem of
growing concern [5–7], common in older adults [5,7,8] and it has been linked to adverse
health outcomes such as falls [9], poorer cognitive function [10] and cancer [11]. 25(OH)D
concentrations decrease with age, due to a reduction in cutaneous vitamin D synthesis [12],
and to the possible decline in the ability of the kidney to synthesize 1,25(OH)2D [4].
Despite the well-known consequences of vitamin D deficiency in bone health [13], this hor-
mone seems to also have a key-role in skeletal muscle [14], namely influencing its function
and performance [14,15]. Frailty increases with age and its prevalence in the community
ranges from 4.0-59.1%, depending on the definition adopted [16]. It is associated with an
increased risk of adverse health outcomes, such as falls, disability, hospitalization and even
mortality [17]. Evidence has shown a link between frailty and vitamin D status, with frailty
being associated with lower levels of serum 25(OH)D [18]. However, the impact of vitamin D
deficiency in frailty status in later life is still unknown.
Obesity has also increased appreciably worldwide and older adults are no exception [19].
Several meta-analyses reported a significant association with lower serum 25(OH)D concen-
trations [20–22], although the mechanisms underlying this association are not yet fully under-
stood. Furthermore, obesity has also been positively associated with frailty status in older
adults [23,24], but it remains to be studied whether frail obese older adults are at higher risk of
vitamin D deficiency and if the presence of these conditions could simultaneously lead to
worse health outcomes. According to the previously described in literature, obese older adults
may be predisposed to vitamin D deficiency, which is in turn associated with worse physical
function and frailty [18,25]. Conversely, frailty may impact the amount of sun exposure and,
consequently, predispose to vitamin D deficiency. Even though several studies have evaluated
the association of frailty status and obesity on vitamin D levels separately [18,20,21], to our
knowledge, literature regarding the study of all three conditions is absent. It will be relevant to
know if frail obese older adults are more likely to present low vitamin D levels. Besides body
mass index (BMI), other obesity indicators such as waist circumference (WC), body roundness
index (BRI) and body shape index (ABSI) may be used [26,27]. While previous studies have
established a link between several indices and vitamin D status, such as BMI and WC [28,29],
data regarding BRI and ABSI is lacking. Thus, we hypothesized that these indices may be asso-
ciated with vitamin D levels, as higher values may denote worse vitamin D status.
Frailty, obesity and vitamin D deficiency are potentially preventable or treatable. Early
interventions in these conditions may lead to an improvement in health status and quality of
life during the course of aging [30]. So, it is important to elucidate the association between
these conditions to target the individuals at risk. Therefore, the aim of this study is to evaluate
the association between serum 25(OH)D concentrations, frailty and obesity, but also to exam-
ine if there is an interaction effect between frailty and obesity on 25(OH)D levels. In addition,
25(OH)D levels, frailty and obesity indices
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the association of other obesity indicators, such as WC, BRI and ABSI, with vitamin D status
will also be explored.
Materials and methods
The study sample included individuals enrolled in the Nutrition UP 65 study, a cross-sectional
observational study conducted in Portugal. As described in detail previously [31], a cluster
sample of 1500 individuals with 65 years or older, representative of the Portuguese older popu-
lation in terms of age, sex, education and regional area was selected. In each regional area,
three or more town councils with>250 inhabitants were randomly selected, and potential
community-dwelling participants were contacted via home approach, telephone or via institu-
tions such as town councils and parish centres. Individuals presenting any condition that pre-
cluded the collection of venous blood samples or urine (eg, dementia or urinary incontinence)
were not included.
Data were gathered between December 2015 and June 2016. A structured questionnaire
was applied by interview, conducted by eight trained registered nutritionists and anthropo-
metric data were also collected. From the initial sample, forty-six individuals could not be
assessed regarding frailty status (n = 43) and body mass index (n = 4) due to missing data and
were therefore excluded from the present analysis. Additionally, seven older adults were also
excluded due to missing data regarding the covariates.
Anthropometric and functional measurements
Anthropometric measurements were collected following standard procedures [32]. A cali-
brated stadiometer (SECA 213, SECA GmbH, Hamburg, Germany) with 0.1 cm resolution
was used to measure standing height. Body weight (in kilograms) was measured with a cali-
brated portable electronic scale (SECA 803, SECA GmbH, Hamburg, Germany) with 0.1 kg
resolution, with the participants wearing light clothes. When it was not possible to measure
standing height or weigh a participant, height was obtained indirectly from non-dominant
hand length [32], measured with a calibrated caliper (Fervi Equipment) with 0.1 centimeter
resolution and body weight was estimated from mid-upper arm and calf circumferences [33].
Mid-upper arm, waist and calf circumferences were measured with a metal tape (Lufkin W606
PM, Lufkin1, Sparks, Maryland, USA), with 0.1 cm resolution. Triceps skinfold thickness was
obtained using a Holtain Tanner/Whitehouse (Holtain, Ltd., Crosswell, United Kingdom)
skinfold caliper, with 0.2 mm resolution.
Hand grip strength (HGS) was measured in the non-dominant hand with a calibrated
Jamar Plus Digital Hand Dynamometer (Sammons Preston Inc., Bolingbrook, Illinois, USA).
As recommended by the American Society of Hand Therapists, participants were asked to sit
in a chair without arm rest, with their shoulders adducted, their elbows flexed 90˚ and their
forearms in neutral position [34]. Three measurements with a one-minute pause between
them were performed by each individual and the higher value, recorded in kilogram-force
(kgf), was used for the analysis. Individuals unable to perform the measurement with the non-
dominant hand were asked to use the dominant hand.
Walking time was measured over a distance of 4.6 meters, in an unobstructed corridor.
Individuals were instructed to walk at usual pace and walking time was recorded by a chro-
nometer (School electronic stopwatch, Dive049, Topgim, Portugal), in seconds. Those unable
to perform the test due to mobility or balance limitations were considered frail for this crite-
rion (n = 28).
Self-reported exhaustion was measured using two items from the Center for Epidemiologic
Studies Depression Scale (CES-D) [35]. The following two statements were read: “I felt that
25(OH)D levels, frailty and obesity indices
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everything I did was an effort” and “In the last week I could not get going.” The exhaustion cri-
terion was considered present if a participant answered “a moderate amount of the time” or
“most of the time” to the question: “How often in the last week did you feel this way?”.
Physical activity, assessed by the short form of the International Physical Activity Question-
naire [36], included information regarding the previous seven days, namely on how many
days and how much time the participant spent: walking or hiking (at home or at work, moving
from place to place, for recreation or sport), sitting (at a desk, visiting friends, reading, study-
ing or watching television), moderate activities (carrying light objects, hunting, carpentry, gar-
dening, cycling at a normal pace or tennis in pairs) and vigorous activities, namely lifting
heavy objects, agriculture, digging, aerobics, swimming, playing football and cycling at a fast
pace was gathered.
Frailty status
Frailty was defined according to Fried et al. frailty phenotype [17]. Pre-frailty was classified as
the presence of one or two, and frailty as the presence of three or more of the following five cri-
teria: “shrinking”: evaluated by self-reported unintentional weight loss (>4.5 kg lost uninten-
tionally in prior year); “weakness”: assessed by low HGS adjusted for sex and BMI; “poor
endurance and energy”: evaluated by self-reported exhaustion; “slowness”: identified by walk-
ing time adjusted for sex and standing height and “low physical activity”: by means of energy
expended per week, adjusted for sex (men <383 kcal/week and women<270 kcal/week).
Laboratory analyses
Qualified nurses collected blood samples for these analyses, preferentially after a 12-hour fast-
ing period. Vitamin D status was evaluated by dosing the plasmatic levels of 25-hydroxychole-
calciferol through electrochemiluminescence immunoassay, using Roche Cobas Vitamin D
total assay reagent (Roche Diagnostics GmbH, Mannheim, Germany). All samples were ana-
lyzed with the same equipment. Since 25(OH)D serum concentrations were very low in our
sample, 25(OH)D concentrations were categorized into quartiles (Q). For characterization
purposes individuals were still classified according to the Institute of Medicine (IOM) criteria
as being at risk of deficiency at serum 25(OH)D concentrations <12 ng/mL, at risk for inade-
quacy at levels ranging from 12–<20 ng/mL and having sufficient levels when 25(OH)D con-
centrations are20 ng/mL [37]. Data concerning 25(OH)D levels in Nutrition UP 65 study
were previously described [8,38].
Obesity indices
BMI was calculated as (weight (kg)/ height2 (m)), and subjects were classified as underweight
for BMI below 20.0 kg/m2, for individuals younger than 70 years of age, and below 22.0 kg/m2
for individuals with 70 years and older, as normal weight for BMI between 20.0 or 22.0-24.9
kg/m2, as pre-obese for BMI between 25.0-29.9 kg/m2 and as obese for BMI of 30.0 kg/m2 or
above [39,40]. Underweight individuals were included in the reference group (“normal
weight”) for the multinomial logistic regression analyses. WC was categorized according to the
risk of metabolic complications as increased (men >94 cm; women >80 cm) and substantially
increased (men >102 cm; women >88 cm) [41]. BRI was calculated based on WC (m) and
25(OH)D levels, frailty and obesity indices
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ABSI (m11/6kg-2/3) was calculated according to the following formula, based on WC (m),
BMI (kg/m2) and height (m) [26]:
ABSI ¼
WC
BMI2=3  height1=2
Quartiles of BRI and ABSI were calculated.
Variables collection and categorization
Information regarding educational level, smoking status, alcohol consumption and vitamin D
supplementation was self-reported. Educational level was determined by the number of com-
pleted school years and the following categories were used: without schooling, 1–4 years, 5-12
years and>12 years. All individuals reported information on smoking status and this informa-
tion was included as a dichotomous variable: smoker or non-smoker. Alcohol consumption
was evaluated as the number of alcoholic drinks daily and was included in the analyses as a cat-
egorical variable: none, moderate consumption (women 1 and men 2 alcoholic drinks
daily), and excessive consumption (women > 1 and men > 2 alcoholic drinks daily). The Por-
tuguese version of the Mini Mental State Examination was used to ascertain cognitive decline,
which was dichotomized into not impaired and impaired. Cut-off scores for cognitive
impairment were the following: individuals with no education,15 points; 1 to 11 years of
years of school completed,22 points; and>11 years of school completed,27 points [42].
Season of blood collection was presented as a dichotomous variable: spring/summer or
autumn/winter. Skin phenotype was defined according to the Fitzpatrick classification [43],
and categorized as follows: red-haired with freckles or fair-haired people; dark-haired or Latin
people; and Arab, Asian or Black people. Vitamin D supplements use was categorized as: no
use, use of vitamin D supplements, unknown composition or use.
Ethics
This research was conducted according to the guidelines established by the Declaration of Hel-
sinki, and the study protocol was approved by the Ethics Committee of the Department of
"Ciências Sociais e Saúde” (Social Sciences and Health) from the “Faculdade de Medicina da
Universidade do Porto” (PCEDCSS–FMUP 15/2015) and by the Portuguese National Commis-
sion of Data Protection (9427/2015). All study participants signed an informed consent form.
Statistical analyses
Descriptive analyses were conducted to compare participants’ characteristics across 25(OH)D
quartiles. Results were presented as number of participants (percentage), for categorical vari-
ables. For continuous variables, means (standard deviations) were used, or medians (inter-
quartile range) to report variables with skewed distribution. ANOVA or Kruskal-Wallis were
used to compare continuous variables between the study groups. Multiple comparisons
between frailty and obesity groups were performed using Dunn-Bonferroni tests. Differences
in proportions, as well comparison between included and excluded individuals, in the sensitiv-
ity analysis, were tested using Chi-square test or Fisher’s exact test.
25(OH)D levels, frailty and obesity indices
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A multinomial logistic regression was carried out to quantify the association between 25
(OH)D quartiles (dependent variable) and independent variables. Odds ratios (OR) and their
respective 95% confidence intervals (CI) were calculated, with adjustments for sex, age, educa-
tional level, smoking status, alcohol consumption, cognitive function, season of blood collec-
tion, vitamin D supplementation and skin phenotype. A stepwise approach with forward entry
was carried out to explore the following interactions terms in each model: frailty statusBMI,
frailty statusWC, frailty statusBRI and frailty statusABSI.
Statistical significance was established at a p-value<0.05. All statistical analyses were con-
ducted with IBM SPSS Statistics 23 (SPSS, Inc, an IBM Company, Chicago, IL).
Results
Descriptive data of the 1447 older adults (57.8% women) included in this study and statistical
differences in sociodemographic lifestyle and health conditions according to 25(OH)D quar-
tiles are shown in Table 1. Median age of the individuals was 74 years (range 65–100). Based
on Fried’s frailty definition, 21.4% were frail and 39.1% were obese according to BMI. Overall,
the majority of the older adults were non-smokers, however slightly more than half (51.3%)
reported consuming alcoholic drinks daily.
Regarding vitamin D serum levels, 69% of participants had 25(OH)D <20 ng/mL, and
39.7% had 25(OH)D <12 ng/mL. Additionally, only 5.3% reported the use of vitamin D sup-
plements. Median 25(OH)D levels of Q1 were 5.6 ng/mL (interquartile range (IQR): 3.0 ng/
mL), for Q2 were 11.5 ng/mL (IQR: 2.9 ng/mL), for Q3 were 17.9 ng/mL (IQR: 3.6 ng/mL)
and, lastly, for Q4 were 29.2 (IQR: 8.7 ng/mL). When studying participants’ characteristics
according to 25(OH)D quartiles, significant differences were observed for all studied variables,
except for smoking status. As expected, individuals that reported the use of vitamin D supple-
ments were more likely to present higher 25(OH)D serum values and to fit in the fourth quar-
tile (p<0.001). Moreover, a higher proportion of frail (p<0.001), obese (p<0.001) and
cognitive impaired (p = 0.001) older adults was observed in the first quartile of 25(OH)D lev-
els. Median values of WC and BRI, and mean values of ABSI decreased across 25(OH)D quar-
tiles (p<0.001).
Sensitivity analysis comparing excluded and included older adults in the present study,
showed that those who were excluded reported a lower alcohol consumption (p = 0.001), were
more likely to be cognitively impaired (p = 0.049) and to have a darker skin phenotype
(p = 0.002) (S1 Table).
Regarding coexistence of frailty and obesity (S2 Table), approximately 75% of older adults
presenting both frailty and obesity were women and nearly 67% were aged over 75 years. More
than 60% of the participants with at least one condition (either frailty or obesity or both) were
women (p<0.001). Individuals presenting only obesity were more likely to be younger (65.0%)
and 70.9% of the older adults presenting only frailty were in the oldest age category (p<0.001).
Median 25(OH)D values decreased across obesity and frailty status and were 17.1 ng/mL for
non-obese non-frail individuals, 13.7 ng/mL for obese non-frail individuals, 10.1 ng/mL for
non-obese frail individuals and 9.2 ng/mL in individuals presenting both obesity and frailty
(p<0.001) (S2 Table).
To evaluate the association between BMI, WC, BRI and ABSI, Spearman correlation coeffi-
cients were also calculated. BMI was positively and significantly correlated with WC (ρ = 0.748),
BRI (ρ = 0.824) and negatively correlated with ABSI (ρ = -0.121). However, ABSI correlated
positively and significantly with WC (ρ = 0.476) and BRI (ρ = 0.358) (S3 Table).
Comparisons of median 25(OH)D serum levels between obesity and frailty status groups,
are displayed in Fig 1. Median 25(OH)D levels in all groups were below 20 ng/ml. In women,
25(OH)D levels, frailty and obesity indices
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Table 1. Characteristics of the 1447 included older adults by 25(OH)D quartiles.
25(OH)D, N (%)
Q1
(3.0–8.7 ng/mL)
360 (24.9)
Q2
(8.8–14.3 ng/mL)
364 (25.2)
Q3
(14.4–22.9 ng/mL)
361 (24.9)
Q4
(23.0–178.1 ng/mL)
362 (25.0)
p-value
Sex
Women 246 (68.3) 221 (60.7) 186 (51.5) 184 (50.8) <0.001a
Men 114 (31.7) 143 (39.3) 175 (48.5) 178 (49.2)
Age (years)
65–75 127 (35.3) 214 (58.8) 238 (65.9) 247 (68.2) <0.001a
>75 233 (64.7) 150 (41.2) 123 (34.1) 115 (31.8)
Education level
Without schooling 84 (23.3) 70 (19.2) 25 (6.9) 26 (7.2) <0.001a
1–4 years 242 (67.2) 243 (66.8) 262 (72.6) 245 (67.7)
5–12 years 24 (6.7) 39 (10.7) 56 (15.5) 64 (17.7)
>12 years 10 (2.8) 12 (3.3) 18 (5.0) 27 (7.5)
Smoking status
Non-smoker 345 (95.8) 346 (95.1) 343 (95.0) 347 (95.9) 0.909a
Smoker 15 (4.2) 18 (4.9) 18 (5.0) 15 (4.1)
Alcohol consumption
None 222 (61.7) 194 (53.3) 160 (44.3) 129 (35.6) <0.001a
Moderate (W: 1/day; M:2/day) 117 (32.5) 136 (37.4) 156 (43.2) 188 (51.9)
Excessive (W: >1/day; M: >2/day) 21 (5.8) 34 (9.3) 45 (12.5) 45 (12.4)
Cognitive function (MMSE)
Not impaired 324 (90.0) 345 (94.8) 334 (92.5) 352 (97.2) 0.001a
Impaired 36 (10.0) 19 (5.2) 27 (7.5) 10 (2.8)
Frailty status
Normal 30 (8.3) 84 (23.1) 111 (30.7) 127 (35.1) <0.001a
Pre-frailty 195 (54.2) 198 (54.4) 205 (56.8) 187 (51.7)
Frailty 135 (37.5) 82 (22.5) 45 (12.5) 48 (13.3)
BMI categories
Underweight 14 (3.9) 8 (2.2) 6 (1.7) 21 (5.8) <0.001a
Normal weight 41 (11.4) 37 (10.2) 60 (16.6) 52 (14.4)
Pre-obesity 142 (39.4) 157 (43.1) 167 (46.3) 176 (48.6)
Obesity 163 (45.3) 162 (44.5) 128 (35.5) 113 (31.2)
WC (cm), median (IQR)† 102.0 (17.1) 101.2 (14.4) 98.0 (14.5) 96.6 (16.3) <0.001b
WC †
W:80 cm; M:94 cm 27 (7.6) 34 (9.4) 51 (14.2) 67 (18.6) <0.001a
W: 81–88 cm; M: 95–102 cm 49 (13.7) 61 (16.9) 89 (24.8) 103 (28.6)
W: >88 cm; M: >102 cm 281 (78.7) 266 (73.7) 219 (61.0) 190 (52.8)
BRI, median (IQR)† 7.1 (2.6) 6.4 (2.3) 5.8 (2.1) 5.6 (2.3) <0.001b
ABSI (m11/6kg-2/3), mean (SD)† 0.086 (0.005) 0.084 (0.005) 0.083 (0.005) 0.083 (0.006) <0.001c
25(OH)D (ng/mL), median (IQR) 5.6 (3.0) 11.5 (2.9) 17.9 (3.6) 29.2 (8.7) <0.001b
Skin phenotype
Red-haired with freckles or fair-haired people 61 (16.9) 85 (23.4) 91 (25.2) 65 (18.0) 0.014a
Dark-haired or Latin people 277 (76.9) 257 (70.6) 251 (69.5) 286 (79.0)
Arab, Asian or Black people 22 (6.1) 22 (6.0) 19 (5.3) 11 (3.0)
Season of blood collection
Spring/Summer 91 (25.3) 167 (45.9) 208 (57.6) 236 (65.2) <0.001a
Autumn/Winter 269 (74.7) 197 (54.1) 153 (42.4) 126 (34.8)
(Continued)
25(OH)D levels, frailty and obesity indices
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Table 1. (Continued)
25(OH)D, N (%)
Q1
(3.0–8.7 ng/mL)
360 (24.9)
Q2
(8.8–14.3 ng/mL)
364 (25.2)
Q3
(14.4–22.9 ng/mL)
361 (24.9)
Q4
(23.0–178.1 ng/mL)
362 (25.0)
p-value
Vitamin D supplementation
No use 290 (80.6) 315 (86.5) 319 (88.4) 294 (81.2) <0.001a
Use of vitamin D supplements 5 (1.4) 10 (2.7) 15 (4.2) 47 (13.0)
Unknown use or composition 65 (18.1) 39 (10.7) 27 (7.5) 21 (5.8)
W: Women; M: Men; MMSE: Mini Mental State Examination; BMI: Body mass index; WC: Waist circumference; BRI: Body roundness index; ABSI: Body shape index;
SD: Standard Deviation; IQR: Interquartile range. Column percentages may not add to 100% due to rounding.
a Chi-square test;
b Kruskal-Wallis test;
c ANOVA test
†Missing data in 10 individuals (0.7%)
https://doi.org/10.1371/journal.pone.0198650.t001
Fig 1. Differences in median (95% CI) 25(OH)D serum levels between Obesity(-) Frailty(-) (W: n = 359; M: n = 364), Obesity(+)
Frailty(-) (W: n = 263; M: n = 151), Obesity(-) Frailty(+) (W: n = 102; M: n = 56) and Obesity(+) Frailty(+) (W: n = 113; M:
n = 39) groups, in older women (W) and men (M), using Kruskal-Wallis with Dunn-Bonferroni tests for multiple comparisons.
p<0.05 for pairwise comparisons.
https://doi.org/10.1371/journal.pone.0198650.g001
25(OH)D levels, frailty and obesity indices
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median 25(OH)D levels were significantly higher in non-obese non-frail group, comparing
with obese non-frail group [15.7 (IQR: 16.5) vs 12.4 (IQR: 10.2)], p = 0.007; non-obese frail
group [15.7 (IQR: 16.5) vs 10.2 (IQR: 11.9)], p<0.001 and obese frail group [15.7 (IQR: 16.5)
vs 9.0 (IQR: 11.0)], p<0.001. Also, obese non-frail women had significantly higher median 25
(OH)D levels comparing with the obese frail group [12.4 (IQR: 10.2) vs 9.0 (IQR: 11.0)],
p = 0.006. Among men, median 25(OH)D levels were only significantly higher in non-obese
non-frail group, comparing with non-obese frail [17.7 (IQR: 14.0) vs 9.5 (IQR: 9.2)] and obese
frail group [17.7 (IQR: 14.0) vs 10.1 (IQR: 10.8)], p<0.001. However, the obese non-frail group
also presented significantly higher median 25(OH)D levels than non-obese frail [18.4 (IQR:
14.9) vs 9.5 (IQR: 9.2)] and obese frail groups [18.4 (IQR: 14.9) vs 10.1 (IQR: 10.8)], p<0.001
and p = 0.001, respectively.
The association between obesity and frailty status and 25(OH)D quartiles was further inves-
tigated through multivariate multinomial regression (Table 2). Considering the fourth quartile
of serum 25(OH)D as the reference category, pre-frail older adults were 2.65 (95% CI: 1.63–
4.33) times more likely to be in the first quartile of serum 25(OH)D (3.0–8.7 ng/mL), and frail
individuals were 3.77 (95% CI: 2.08–6.83) times more likely to present serum 25(OH)D levels
in the first quartile (P for trend <0.001). For individuals in the two lowest quartiles of serum
25(OH)D levels (Q1: 3.0–8.7 ng/mL and Q2: 8.8–14.3 ng/mL), the adjusted odds ratios for
obesity were 1.74 (95% CI: 1.06–2.86) for the first (P for trend = 0.018) and 2.19 (95% CI:
1.36–3.52) for the second (P for trend = 0.001) quartiles. The association between pre-obesity
and serum 25(OH)D levels did not reach statistical significance in any quartile.
Multinomial logistic regressions were conducted to evaluate the association of WC, BRI
and ABSI with serum 25(OH)D using 25(OH)D quartiles as the dependent variable and the
fourth quartile as the reference category (Table 3). Older adults in the highest category of WC
presented the odds of 3.46 (95% CI: 1.95–6.15) and 2.61 (95% CI: 1.58–4.29) for being in the
first and second serum 25(OH)D levels quartiles, respectively (P for trend<0.001). Although
no significant associations were identified in the third 25(OH)D quartile, a significant trend
was also observed (P for trend = 0.041). The participants in first quartile of serum 25(OH)D
levels showed an increasing adjusted odds ratio for BRI, from the second through the fourth
quartile: 1.69 (95% CI: 1.02–2.79), 2.26 (95% CI: 1.36–3.75) and 4.35 (95% CI: 2.60–7.29), P for
trend<0.001. Regarding ABSI and for the participants placed in the lowest 25(OH)D serum
levels (first) quartile, the odds ratios were 4.03 (95% CI: 2.37–6.86) and 3.17 (95% CI: 1.86–
5.38) for the third and fourth ABSI quartiles, respectively (P for trend <0.001).
In the second quartile of serum 25(OH)D levels, there was also a significant positive associ-
ation with the third BRI quartile (OR: 2.14; 95% CI: 1.37–3.34) and fourth BRI quartile (OR:
2.51; 95% CI: 1.55–4.05), P for trend <0.001. Similarly, the third ABSI quartile was also posi-
tively associated with the second quartile of serum 25(OH)D levels (OR: 1.99; 95% CI: 1.23-
3.21).
Additionally, when an interaction effect between frailty status and obesity indices was tested
statistical differences were not found.
Discussion
In this cross-sectional study an inverse association between frailty and obesity with serum 25
(OH)D concentrations, independently of sex, age, educational level, alcohol consumption,
smoking, skin phenotype, vitamin D supplementation, season of blood collection and cogni-
tive function, was found. These results were consistent with findings of several meta-analyses
which evaluate the association between each of these conditions with vitamin D deficiency
[18,20,21]. The interaction between frailty and obesity indices concerning serum 25(OH)D
25(OH)D levels, frailty and obesity indices
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Table 2. Multinomial logistic regression regarding frailty status and body mass index with 25(OH)D quartiles. Reference category was the fourth quartile of serum
25(OH)D (23.0–178.1 ng/mL)†.
25(OH)D
Q1
(3.0–8.7 ng/mL)
Q2
(8.8–14.3 ng/mL)
Q3
(14.4–22.9 ng/mL)
Crude
OR (95% CI)
Adjusted
OR (95% CI)
Crude
OR (95% CI)
Adjusted
OR (95% CI)
Crude
OR (95% CI)
Adjusted
OR (95% CI)
Frailty status
Normal 1.00 1.00 1.00 1.00 1.00 1.00
Pre-frailty 4.41 (2.83–6.89) 2.65 (1.63–4.33) 1.60 (1.14–2.25) 1.18 (0.81–1.72) 1.25 (0.91–1.73) 1.12 (0.79–1.60)
Frailty 11.91 (7.10–19.96) 3.77 (2.08–6.83) 2.58 (1.65–4.05) 1.30 (0.77–2.19) 1.07 (0.66–1.73) 0.76 (0.45–1.31)
P for trend <0.001 <0.001 <0.001 0.235 0.612 0.405
BMI categories
Underweight/Normal weight 1.00 1.00 1.00 1.00 1.00 1.00
Pre-obesity 1.07 (0.71–1.62) 1.28 (0.80–2.07) 1.45 (0.94–2.22) 1.58 (0.99–2.48) 1.05 (0.71–1.56) 1.11 (0.74–1.68)
Obesity 1.92 (1.25–2.93) 1.74 (1.06–2.86) 2.33 (1.49–3.62) 2.19 (1.36–3.52) 1.25 (0.83–1.90) 1.28 (0.83–1.99)
P for trend <0.001 0.018 <0.001 0.001 0.200 0.228
Sex
Women 1.00 1.00 1.00 1.00 1.00 1.00
Men 0.48 (0.35–0.65) 0.83 (0.57–1.21) 0.67 (0.50–0.90) 0.93 (0.66–1.32) 0.97 (0.73–1.30) 1.08 (0.77–1.51)
Age (years)
65–75 1.00 1.00 1.00 1.00 1.00 1.00
>75 3.94 (2.89–5.37) 1.73 (1.19–2.51) 1.51 (1.11–2.04) 0.98 (0.68–1.39) 1.11 (0.81–1.51) 0.97 (0.69–1.38)
Education level
Without schooling 1.00 1.00 1.00 1.00 1.00 1.00
1–4 years 0.31 (0.19–0.49) 0.62 (0.37–1.05) 0.37 (0.23–0.60) 0.49 (0.29–0.83) 1.11 (0.63–1.98) 1.24 (0.68–2.26)
5–12 years 0.12 (0.06–0.22) 0.28 (0.14–0.57) 0.23 (0.12–0.41) 0.33 (0.17–0.63) 0.91 (0.47–1.75) 1.06 (0.53–2.11)
>12 years 0.12 (0.05–0.27) 0.43 (0.16–1.12) 0.17 (0.07–0.37) 0.28 (0.12–0.68) 0.69 (0.31–1.56) 0.86 (0.36–2.04)
Smoking status
Non-smoker 1.00 1.00 1.00 1.00 1.00 1.00
Smoker 1.01 (0.48–2.09) 2.18 (0.93–5.07) 1.20 (0.60–2.43) 1.94 (0.91–4.12) 1.21 (0.60–2.45) 1.41 (0.67–2.94)
Alcohol consumption
None 1.00 1.00 1.00 1.00 1.00 1.00
Moderate (W1/day; M2/day) 0.36 (0.26–0.50) 0.61 (0.42–0.89) 0.48 (0.35–0.66) 0.59 (0.41–0.84) 0.67 (0.49–0.92) 0.69 (0.49–0.98)
Excessive (W>1/day; M>2/day) 0.27 (0.16–0.48) 0.52 (0.27–0.98) 0.50 (0.31–0.83) 0.62 (0.36–1.07) 0.81 (0.50–1.30) 0.85 (0.51–1.42)
Cognitive function (MMSE)
Not impaired 1.00 1.00 1.00 1.00 1.00 1.00
Impaired 3.91 (1.91–8.01) 2.43 (1.09–5.38) 1.94 (0.89–4.23) 1.66 (0.72–3.82) 2.85 (1.36–5.97) 2.81 (1.29–6.13)
Skin phenotype
Red-haired with freckles or fair-haired people 1.00 1.00 1.00 1.00 1.00 1.00
Dark-haired or Latin people 1.03 (0.70–1.52) 1.24 (0.81–1.91) 0.69 (0.48–0.99) 0.76 (0.52–1.12) 0.63 (0.44–0.90) 0.64 (0.44–0.93)
Arab, Asian or Black people 2.13 (0.95–4.76) 1.88 (0.77–4.56) 1.53 (0.69–3.38) 1.43 (0.62–3.28) 1.23 (0.55–2.77) 1.17 (0.51–2.68)
Season of blood collection
Spring/Summer 1.00 1.00 1.00 1.00 1.00 1.00
Autumn/Winter 5.54 (4.02–7.64) 4.46 (3.08–6.46) 2.21 (1.64–2.98) 2.10 (1.50–2.95) 1.38 (1.02–1.86) 1.48 (1.06–2.07)
Vitamin D supplementation
No use 1.00 1.00 1.00 1.00 1.00 1.00
Use of vitamin D supplements 0.11 (0.04–0.28) 0.08 (0.03–0.20) 0.20 (0.10–0.40) 0.16 (0.08–0.34) 0.29 (0.16–0.54) 0.26 (0.14–0.49)
Unknown use or composition 3.14 (1.87–5.27) 1.75 (0.99–3.08) 1.73 (0.99–3.02) 1.18 (0.66–2.12) 1.19 (0.66–2.14) 1.07 (0.58–1.98)
BMI: Body mass index; W: Women; M: Men; OR: Odds ratio; CI: Confidence interval; MMSE: Mini Mental State Examination
†Adjusted for all covariates included in the table. Bold text indicates a statistically significant difference with a p-value less than 0.05.
p<0.001
https://doi.org/10.1371/journal.pone.0198650.t002
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was further explored but no significant results were found, meaning that frailty and obesity are
independently associated with lower serum 25(OH)D levels, and the effect of frailty (or obe-
sity) on serum 25(OH)D levels is the same at all levels of obesity (or frailty).
When we compared vitamin D levels between frailty and obesity groups we found decreas-
ing 25(OH)D concentrations across them. Thus, individuals that were not frail or obese pre-
sented higher unadjusted median 25(OH)D serum concentrations than the other study
participants. Interestingly, when data were stratified by sex the pattern was very similar in
women, however results were not as evident among men. These observations were supported
after by the results of logistic regression, which revealed an association between these condi-
tions and lower serum 25(OH)D levels.
All obesity indicators evaluated were inversely associated with 25(OH)D serum concentra-
tions. Regarding BMI, an inverse association between 25(OH)D levels and obesity was found,
but not for pre-obesity. Moreover, being at the fourth quartile of BRI was associated with a
four-fold increased risk of presenting 25(OH)D levels in the first quartile, and it was more
strongly associated than the other studied obesity indicators. It was also observed that the odds
of being in the first quartile of 25(OH)D increased significantly across BRI quartiles.
Physiological changes that occur with aging predispose older adults to lower levels of serum
25(OH)D and frailty status. In addition, lower vitamin D concentrations may also have a nega-
tive impact on frailty status through multiple pathways. It has been previously demonstrated
that vitamin D was linked with physical function, muscle strength and physical activity
Table 3. Association between waist circumference, body roundness index and body shape index with 25(OH)D quartiles. Multinomial logistic regression models.
Reference category was the fourth quartile of serum 25(OH)D (23.0–178.1 ng/mL)†.
25(OH)D
Q1
(3.0–8.7 ng/mL)
Q2
(8.8–14.3 ng/mL)
Q3
(14.4–22.9 ng/mL)
Crude
OR (95% CI)
Adjusted†
OR (95% CI)
Crude
OR (95% CI)
Adjusted†
OR (95% CI)
Crude
OR (95% CI)
Adjusted†
OR (95% CI)
Waist circumference (WC)¶
W: 80cm; M:94cm 1.00 1.00 1.00 1.00 1.00 1.00
W: 81–88 cm; M: 95–102 cm 1.18 (0.67–2.07) 1.31 (0.69–2.48) 1.17 (0.69–1.96) 1.27 (0.73–2.20) 1.14 (0.72–1.80) 1.23 (0.76–1.98)
W: >88 cm; M: >102 cm 3.67 (2.26–5.95) 3.46 (1.95–6.15) 2.76 (1.75–4.34) 2.61 (1.58–4.29) 1.51 (1.00–2.29) 1.56 (0.99–2.45)
P for trend <0.001 <0.001 <0.001 <0.001 0.019 0.041
Body roundness index (BRI)¶
Q1 (1.93–5.09) 1.00 1.00 1.00 1.00 1.00 1.00
Q2 (5.10–6.10) 1.78 (1.14–2.78) 1.69 (1.02–2.79) 1.68 (1.12–2.52) 1.51 (0.98–2.31) 1.27 (0.87–1.86) 1.15 (0.77–1.71)
Q3 (6.11–7.49) 2.88 (1.85–4.50) 2.26 (1.36–3.75) 2.48 (1.64–3.75) 2.14 (1.37–3.34) 1.56 (1.05–2.32) 1.45 (0.95–2.20)
Q4 (7.50–15.83) 6.91 (4.41–10.80) 4.35 (2.60–7.29) 3.35 (2.16–5.20) 2.51 (1.55–4.05) 1.42 (0.91–2.23) 1.31 (0.81–2.12)
P for trend <0.001 <0.001 <0.001 <0.001 0.090 0.218
Body shape index (ABSI)¶
Q1 (0.0643–0.0803) 1.00 1.00 1.00 1.00 1.00 1.00
Q2 (0.0804–0.0840) 1.55 (0.99–2.42) 1.59 (0.96–2.63) 1.31 (0.89–1.95) 1.33 (0.87–2.04) 0.93 (0.63–1.37) 0.91 (0.60–1.38)
Q3 (0.0841–0.0874) 3.55 (2.27–5.56) 4.03 (2.37–6.86) 1.81 (1.19–2.76) 1.99 (1.23–3.21) 1.46 (0.96–2.20) 1.40 (0.88–2.22)
Q4 (0.0875–0.1034) 3.17 (2.06–4.88) 3.17 (1.86–5.38) 1.30 (0.86–1.97) 1.29 (0.79–2.09) 0.95 (0.63–1.44) 0.87 (0.54–1.39)
P for trend <0.001 <0.001 0.115 0.240 0.846 0.691
OR: Odds ratio; CI: Confidence interval; W: Women; M: Men.
†Adjusted for sex, age, educational level, alcohol consumption, smoking, skin phenotype, vitamin D supplementation, season of blood collection and cognitive function
and frailty status. Waist circumference was further adjusted for height. Bold text indicates a statistically significant difference with a p-value less than 0.05.
¶Missing data in 10 individuals.
p<0.001
https://doi.org/10.1371/journal.pone.0198650.t003
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[25,44,45]. Accordingly, results from several clinical trials carried out in older adults showed
that vitamin D supplementation had a beneficial effect in muscle strength and function [15].
Evidence suggests the presence of vitamin D receptors (VDR) in the muscle, which mediate
multiple effects [46]. Furthermore, several mechanisms have been suggested to explain the
association between muscle function and vitamin D deficiency. In more depth, vitamin D may
play an important role in muscle, mediated by several signaling pathways derived from geno-
mic and non-genomic actions of VDR. These mechanisms include regulation of calcium
homeostasis, cell proliferation and differentiation, fibers size and protection against insulin
resistance, fatty degeneration of the muscle and arachidonic acid mobilization [47]. Neverthe-
less, this receptor was recently found to be undetectable in skeletal muscle, which brings this
issue to the fore [48]. On the other hand, frailty may contribute to lower 25(OH)D levels, since
frail older adults may spend fewer hours engaged in outdoor activities and, consequently, have
a reduced sunlight exposure.
Present study results are also consistent with previous data reporting an inverse relationship
between 25(OH)D levels and increased adiposity [20–22,28,29]. Besides vitamin D deficiency
being frequent in older adults, it is also common in obese people. A possible explanation is
that obese individuals usually have less skin exposed compared with normal weight individuals
[49]. Nevertheless, we were unable to evaluate sunlight exposure in the present research. A
study which intended to explore the causality and direction of this association using genetic
markers, revealed that a higher BMI leads to lower 25(OH)D concentrations [50]. In addition,
improvement in circulating levels of 25(OH)D was observed in pre-obese and obese after a
weight loss intervention [51,52]. Since adipose tissue acts as a reservoir for vitamin D, it has
been hypothesized that inadequate levels of vitamin D in obese individuals may be predisposed
by the sequestration of vitamin D by fat tissue [53]. However, it has been recently suggested
that this association may be related to a simple volumetric dilution due to higher volume of
distribution of 25(OH)D in the adipose tissue [54]. Therefore, it is expected that individuals
with higher levels of adiposity may be predisposed to inadequate serum 25(OH)D concentra-
tions. Supporting the volumetric dilution hypothesis, a higher dose was required to produce
the desired increment in serum 25(OH)D concentrations among obese individuals [55]. This
supports the Endocrine Society guidelines, which state that the therapy should be adjusted in
the presence of obesity [1]. Also, evidence suggests that adipocytes express VDR [56],
25-hydroxylase [57] and 1α-hydroxylase enzymes [57,58] which are involved in vitamin D
metabolism. Interestingly these enzymes seem to have a decreased expression in obesity [57].
BMI and WC are traditionally chosen as anthropometric indicators of general and abdomi-
nal adiposity, respectively. Nevertheless, in the present study, the other obesity indices evalu-
ated (BRI and ABSI), were positively associated with lower vitamin D levels, showing that
these may also be used as alternative obesity indicators to identify older adults at risk of low 25
(OH)D levels. Despite the lack of positive correlation between ABSI and BMI, our study also
demonstrated the link between these indices and lower vitamin D levels, which reinforces
their utility.
The present study has some limitations. Firstly, this was a cross-sectional study, therefore
the possibility of reverse causation should not be excluded. Secondly, although we have
adjusted for multiple covariates, the possible occurrence of residual confounding cannot be
ruled out. Thirdly, serum 25(OH)D concentrations were measured using electrochemilumi-
nescence immunoassay, when liquid chromatography-tandem mass spectrometry is consid-
ered the golden standard, which can introduce variability in the results [59]. And, lastly,
participants’ sun exposure levels were not assessed.
In contrast, some strengths can also be pointed out. To our knowledge, this is the first study
to explore the association of BRI and ABSI with serum 25(OH)D levels and to elucidate the
25(OH)D levels, frailty and obesity indices
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impact of both obesity and frailty status on 25(OH)D serum levels. Moreover, for all the stud-
ied participants, vitamin D was dosed with the same method, the same equipment and in the
same laboratory. The very low serum 25(OH)D levels in our sample, with only 30% of the sam-
ple presenting adequate 25(OH)D serum concentrations, allowed to study this association.
In summary, present results show that frailty and all obesity indices included, such as BMI,
WC, BRI and ABSI, are inversely associated with serum 25(OH)D concentrations. Further-
more, these associations were independent, as no interaction effect between frailty and obesity
concerning 25(OH)D levels was found. As discussed above, several studies reported conflicting
results, however present results reinforce the positive relationship between vitamin D defi-
ciency and both frailty and obesity. Plus, they emphasize the need to target obese and frail
older people and monitoring their serum vitamin D levels with special care. Nevertheless, lon-
gitudinal studies are necessary to fully elucidate these associations.
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44. Visser M, Deeg DJH, Lips P. Low Vitamin D and High Parathyroid Hormone Levels as Determinants of
Loss of Muscle Strength and Muscle Mass (Sarcopenia): The Longitudinal Aging Study Amsterdam. J
Clin Endocrinol Metab. 2003; 88: 5766–5772. https://doi.org/10.1210/jc.2003-030604 PMID: 14671166
45. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Hu FB, Zhang Y, Karlson EW, et al. Higher 25-hydroxyvitamin
D concentrations are associated with better lower-extremity function in both active and inactive persons
aged > or = 60 y. Am J Clin Nutr. 2004; 80: 752–8. https://doi.org/10.1093/ajcn/80.3.752 PMID:
15321818
46. Bischoff HA, Borchers M, Gudat F, Duermueller U, Theiler R, Stähelin HB, et al. In situ detection of
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